Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey

Countries covered: United States Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. This report allows you to: Understand what occurs with actual patients Access the most up-to-date prescribing trends Gain actionable data for developing and improving your market strategies Pinpoint needs of your target audience Focus resources to maximize the effectiveness of your budget Understand where your product fits Understand where your competitor’s product fits Design messages to advance brand performance

Additional Information

Report Excerpts

Metastatic prostate cancer is a cancer that has spread outside the prostate gland to the bladder or rectum as well as lymph nodes, bones or other areas. While treatment can control its spread and related symptoms, currently no treatment provides a cure. Treatment selection depends on many factors including previous treatment, site of recurrence, comorbid conditions, and patient preferences. Some men with a rising prostate-specific antigen (PSA) are treated similarly to those with advanced prostate cancer. In prostate cancer, testosterone can cause prostate tumors to grow. Drugs, surgery, and other hormones are used to reduce testosterone or to block it. Androgen deprivation therapy (ADT) is usually recommended first. If cancer returns following ADT, the cancer is termed androgen resistant. In addition to ADT, secondary hormone therapy may be considered. When patients stop responding to all forms of hormone treatment, the cancer is termed castrate resistant prostate cancer. The next step in treatment is chemotherapy or immunotherapy. If cancer spreads to the bones, ADT may control the cancer that has spread to the bones. Radiation may also relieve the pain.